Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Prescription Drugs & Other Medical Products

Reports

Displaying 11 - 20 of 112. 10 per page. Page 2.

Advanced Search
ASPE Issue Brief

How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief

November 30, 2020
How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief Robin Ghertner and Mir M. Ali U.S. Department of Health and Human Services

Medicare FFS Part B and International Drug Prices: A Comparison of the Top 50 Drugs

November 19, 2020
The September 13, 2020 Executive Order on Lowering Drug Prices by Putting America First declared, “It is the policy of the United States that the Medicare program should not pay more for costly Part B or Part D prescription drugs or biological products than the most-favored-nation price.” The Most Favored Nation (MFN) Model issued by the Centers for Medicare & Medicaid Services (CMS) on No

Medicare Part B Drugs: Trends in Spending and Utilization, 2006-2017

November 19, 2020
Medicare covers prescription drugs provided during inpatient hospital and skilled nursing facility stays through Part A, retail prescription drugs through Part D, and drugs provided in physicians’ offices and hospital outpatient departments through Part B. Over the 2006-17 period, Medicare FFS Part B drugs spending per enrollee grew at 8.1 percent annually.

Comparing Insulin Prices in the U.S. to Other Countries

September 23, 2020
Insulin prices have increased dramatically over the past decade in the United States. This report presents results from international price comparisons of insulins using a price index approach.

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care

July 8, 2020
Treatment providers, policymakers, and others are seeking ways to reverse the tide of mortality and morbidity that has accompanied the opioid epidemic. There are evidence-based treatments for opioid use disorder (OUD), including medication-assisted treatment (MAT) using buprenorphine, methadone, and naltrexone. Research shows that retention in MAT results in better outcomes.
Report

Availability of Treatment for Opioid Use Disorder in Areas of High Foster Care Increases

April 26, 2020
Parental opioid use disorder (OUD) is a risk factor for the maltreatment of children and placement into foster care. Opioid agonist therapy (OAT) is an evidence-based treatment for OUD using medications such as methadone and buprenorphine. OAT can help parents enter recovery and reduce the risk of maltreatment, and potentially improve child welfare outcomes.

Addressing the Opioid Epidemic with Better Data: An Overview of HHS Priorities and Projects to Expand Data Capacity for Patient-Centered Outcomes Research on Opioids

October 30, 2019
This report builds on a workshop sponsored by ASPE, titled Addressing the Opioid Epidemic: Harnessing the Power of Data for Patient-Centered Research in December 2018, which showcased projects working to build the data infrastructure for patient-centered outcomes research around opioids.
Report to Congress

Report to Congress: Prescription Drug Pricing Report

September 25, 2019
The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations.
Report to Congress

Report to Congress: Prescription Drugs: Innovation, Spending, and Patient Access

September 25, 2019
This Report responded to a request from the House and Senate Committees on Appropriations.

Non-Fatal Opioid Overdose and Associated Health Outcomes: Final Summary Report

September 3, 2019
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO.